Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 12/20 | 0.38 |
| ▸ | FEN1 | P39748 | 12/20 | 0.38 |
| ▸ | QPCT | Q16769 | 1/20 | 0.38 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.38 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30477942 | 1.00 | ALOX5AP (0.38) | ALOX5APFEN1QPCTQPCTLACP1 | |
| SCHEMBL29387879 | 0.96 | QPCT (0.37) | ALOX5APFEN1QPCTQPCTLACP1 | |
| SCHEMBL22869354 | 0.96 | QPCT (0.37) | ALOX5APFEN1QPCTQPCTLACP1 | |
| SCHEMBL22869347 | 0.95 | QPCT (0.39) | ALOX5APFEN1QPCTQPCTLACP1 | |
| SCHEMBL29386863 | 0.95 | QPCT (0.39) | ALOX5APFEN1QPCTQPCTLACP1 | |
| SCHEMBL22869370 | 0.89 | MDM2 (0.36) | ALOX5APFEN1QPCTQPCTLACP1 | |
| SCHEMBL29384847 | 0.89 | MDM2 (0.36) | ALOX5APFEN1QPCTQPCTLACP1 | |
| SCHEMBL22869358 | 0.86 | HSD11B1 (0.36) | ALOX5APFEN1QPCTQPCTLACP1 | |
| SCHEMBL29386867 | 0.86 | HSD11B1 (0.36) | ALOX5APFEN1QPCTQPCTLACP1 | |
| SCHEMBL22869318 | 0.85 | QPCT (0.36) | QPCTQPCTLACP1PPARDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111819173-B | CD73 inhibitors | 伊莱利利公司 | 2023-06-06 | — | — | CN | disclosed |
| EP-3759096-B1 | CD73 INHIBITORS | LILLY CO ELI (US) | 2022-02-16 | — | — | EP | disclosed |
| US-11028074-B2 | CD73 inhibitors | ELI LILLY AND COMPANY (US) | 2021-06-08 | — | — | US | disclosed |
| US-20210002257-A1 | CD73 INHIBITORS | ELI LILLY AND COMPANY | 2021-01-07 | — | — | US | disclosed |
| CN-111819173-A | CD73 inhibitor | 伊莱利利公司 | 2020-10-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028074-B2 | CD73 inhibitors | ENTPD5, NT5E, ENTPD1 | ALOX5AP 1313/4885FEN1 231/4885QPCT 1701/4885 |
| US-20210002257-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | ALOX5AP 1313/4885FEN1 231/4885QPCT 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.